Study guide

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions

Key Takeaways Explain This Topic AI

Cocaine competitively blocks monoamine reuptake (DAT, NET, SERT) and produces local anesthetic cardiac sodium channel blockade, widening QRS/QT intervals and predisposing to ventricular arrhythmias; methamphetamine acts as a transport substrate and VMAT-2 inhibitor, causing massive reverse-transport monoamine dumping and irreversible terminal dopaminergic axonal pruning.

Acute stimulant-induced cardiovascular emergencies (hypertensive crisis, coronary vasospasm, myocardial infarction) demand immediate sympatholytic treatment with intravenous benzodiazepines, nitroglycerin, or phentolamine; pure beta-blockers (e.g., propranolol, metoprolol) are strictly contraindicated due to unopposed alpha-1 vasoconstriction.

Stimulant hyperthermia (>40.5°C) and excited delirium drive life-threatening rhabdomyolysis, myoglobinuric acute kidney injury, and DIC; first-line intervention requires high-dose IV benzodiazepines and active cooling, whereas first-generation antipsychotics (haloperidol) are contraindicated as they impair thermoregulation, lower seizure thresholds, and prolong QTc.

There are currently no FDA-approved medications for stimulant use disorders; the landmark ADAPT-2 trial (Trivedi et al., 2021) established the efficacy of combination oral extended-release bupropion 450 mg/day plus injectable extended-release naltrexone 380 mg every 3 weeks for moderate-to-severe methamphetamine use disorder (NNT = 9).

Contingency Management (CM, voucher or fishbowl prize-based reinforcement for objective drug-negative urines) possesses the strongest empirical evidence base and largest effect size for stimulant abstinence and treatment retention, serving as the gold-standard behavioral cornerstone alongside CBT and the 16-week Matrix Model.

Last updated: September 2026

5.1 Stimulant Use Disorder: Neurotoxicity, Medical Emergencies & Evidence-Based Interventions

Quick Answer: Stimulant use disorders involve profound central and peripheral monoaminergic stimulation. Cocaine competitively inhibits presynaptic reuptake via DAT, NET, and SERT, while exerting class I local anesthetic sodium channel blockade that widens the QRS complex and predisposes to malignant ventricular arrhythmias. Methamphetamine acts as a transporter substrate that inhibits vesicular monoamine transporter-2 (VMAT-2) and triggers reverse-transport monoamine dumping, causing long-term terminal dopaminergic axonal pruning. Acute cardiovascular crises (coronary vasospasm, acute myocardial infarction, hypertensive emergency) must be treated with intravenous benzodiazepines , nitroglycerin , or phentolamine ; pure beta-blockers are strictly contraindicated due to the risk of unopposed alpha-1 adrenergic vasoconstriction. Although no FDA-approved pharmacotherapies exist , the landmark ADAPT-2 trial demonstrated that combination extended-release bupropion (450 mg/day) plus injectable extended-release naltrexone (380 mg q3w) significantly improves methamphetamine abstinence. Across all modalities, Contingency Management (CM) maintains the highest effect size and strongest evidence base for stimulant abstinence.

1. Pharmacology & Neurobiology: Cocaine vs. Methamphetamine

Psychostimulants represent a chemically and pharmacologically diverse class of compounds that profoundly enhance monoaminergic neurotransmission—principally dopamine (DA), norepinephrine (NE), and serotonin (5-HT)—within the central and peripheral nervous systems. Understanding the precise molecular distinctions between cocaine and amphetamine derivatives is critical for advanced practice clinical management.

Presynaptic Monoamine Transporter Dynamics

Under baseline physiological conditions, the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT) terminate monoaminergic signaling by clearing neurotransmitters from the synaptic cleft back into the presynaptic terminal. Once internalized, cytosolic monoamines are sequestered into synaptic storage vesicles by vesicular monoamine transporter-2 (VMAT-2) , maintaining low free cytosolic concentrations and protecting monoamines from metabolic degradation by monoamine oxidase (MAO) . PHYSIOLOGICAL MONOAMINE CYCLE:

[Presynaptic Terminal] ──DAT/NET/SERT Internalization──> [Cytosol] ──VMAT-2 Sequestration──> [Synaptic Vesicles]

COCAINE MECHANISM:

[Synaptic Cleft] <── DAT/NET/SERT Blockade (Reuptake Inhibited) ── [Extracellular Monoamine Accumulation]

METHAMPHETAMINE MECHANISM:

[Meth Enters via DAT] ── VMAT-2 Inhibition + pH Disruption ──> [Cytosolic Dumping] ── Transporter Reversal ──> [Massive Synaptic Flooding]

Cocaine: Competitive Reuptake Blockade & Sodium Channel Inhibition

Cocaine is a naturally occurring alkaloid extracted from the leaves of Erythroxylum coca . Its primary pharmacodynamic actions include:

Competitive Reuptake Blockade: Cocaine binds directly to the external substrate-binding pocket of DAT, NET, and SERT without being transported into the neuron. By physically obstructing monoamine reuptake, cocaine causes immediate accumulation of dopamine, norepinephrine, and serotonin within the synaptic cleft, driving intense stimulation of post-synaptic receptors.

Local Anesthetic & Membrane-Stabilizing Cardiotoxicity: Distinct from amphetamines, cocaine binds to and blocks voltage-gated sodium channels ( I Na I_{\text{Na}} I Na ​ ) in myocardial tissue and peripheral nerves. This class IC antiarrhythmic-like membrane-stabilizing action slows Phase 0 cardiac depolarization, widens the QRS complex, prolongs the QTc interval, and significantly elevates the risk of re-entrant ventricular arrhythmias, torsades de pointes, and fatal ventricular fibrillation.

Pharmacokinetics: Cocaine possesses a rapid elimination half-life of 0.5 to 1.5 hours . It is rapidly metabolized by hepatic and serum cholinesterases into benzoylecgonine (detection window in urine: 2 to 4 days; up to 1 to 2 weeks in chronic, high-dose users) and ecgonine methyl ester. When co-ingested with ethanol, hepatic transesterification synthesizes cocaethylene , a metabolite with a prolonged elimination half-life (2 to 2.5 hours), potent DAT binding, and exaggerated arrhythmogenic cardiotoxicity.

Methamphetamine: VMAT-2 Inhibition & Transporter Reversal

Methamphetamine is a synthetic, highly lipid-soluble methylated amphetamine with profound central nervous system penetrance and a markedly prolonged elimination half-life ( 10 to 12 hours ):

Substrate Uptake & Vesicular Depletion: Methamphetamine is structurally homologous to dopamine and acts as a competitive substrate for DAT, NET, and SERT. Once transported into the presynaptic terminal (and diffusing directly across the plasma membrane due to high lipophilicity), methamphetamine targets VMAT-2 . It collapses the vesicular proton electrochemical gradient necessary for monoamine retention and competitively inhibits VMAT-2 function.

Reverse Transport Dumping: Displacement of monoamines from storage vesicles causes an enormous accumulation of free cytosolic dopamine, norepinephrine, and serotonin within the nerve terminal. Methamphetamine subsequently activates protein kinase C (PKC) and CaMKII, prompting reverse transport (efflux) via DAT, NET, and SERT. The transporters reverse directionality, pumping massive surges of cytosolic monoamines into the synaptic cleft independent of neuronal action potentials.

MAO Inhibition: Concurrently, methamphetamine acts as a competitive inhibitor of monoamine oxidase, preventing the intracellular breakdown of accumulated monoamines.

Terminal Axonal Pruning & Striatal Neurotoxicity

Unlike cocaine, which is primarily toxic via acute vascular and cardiac mechanisms, chronic methamphetamine exposure inflicts profound, long-lasting structural damage on central dopaminergic and serotonergic architecture:

Oxidative and Nitrosative Stress: The enormous accumulation of free cytosolic dopamine facilitates non-enzymatic auto-oxidation, generating neurotoxic dopamine quinones , hydrogen peroxide ( H 2 O 2 H_2O_2 H 2 ​ O 2 ​ ), hydroxyl radicals ( ∙ OH \,^\bullet\text{OH} ∙ OH ), and peroxynitrite ( ONOO − \text{ONOO}^- ONOO − ).

Axonal Pruning & Terminal Loss: Reactive oxygen and nitrogen species trigger mitochondrial permeability transition, deplete ATP, activate calpains/caspases, and induce direct damage to structural tubulin and actin microfilaments. This results in axonal pruning —the selective structural degeneration of presynaptic axon terminals in the striatum, caudate, and putamen, while sparing cell bodies in the substantia nigra and ventral tegmental area.

Long-Term Neurochemical Deficits: Positron emission tomography (PET) imaging in patients with chronic methamphetamine use disorder demonstrates profound reductions in striatal DAT density (up to 20–40% loss) and D 2 / D 3 D_2/D_3 D 2 ​ / D 3 ​ receptor availability that persist for 12 to 24 months of verified abstinence. Clinically, this manifesting as profound executive dysfunction, severe protracted anhedonia, apathy, psychomotor slowing, and treatment-resistant depressive states.

Comparative Overview: Cocaine vs. Methamphetamine

Parameter Cocaine Methamphetamine

Primary Mechanism Pure competitive reuptake inhibitor (DAT, NET, SERT) Transport substrate, VMAT-2 inhibitor, reverse transporter exporter

Synaptic Dynamics Blocks reuptake; action-potential dependent release Action-potential independent cytosolic dumping and reverse transport

Elimination Half-Life Short: 0.5 to 1.5 hours Long: 10 to 12 hours

Primary Metabolites Benzoylecgonine, ecgonine methyl ester, cocaethylene (with alcohol) Amphetamine (active), 4-hydroxymethamphetamine, norephedrine

Cardiac Electrophysiology Class IC sodium channel blockade; QRS/QT prolongation, ventricular dysrhythmias Catecholamine excess, myocardial ischemia, dilated cardiomyopathy

Neurostructural Toxicity Functional receptor downregulation; minimal terminal pruning Severe terminal axonal pruning, microglial activation, persistent striatal DAT depletion

2. Acute Medical Emergencies & Crisis Management

Stimulant toxicity precipitates life-threatening medical crises spanning the cardiovascular, central nervous, and renal systems. The APRN in emergency, inpatient, or outpatient triage must rapidly recognize toxidromes and execute evidence-based medical resuscitation.

Cardiovascular Emergencies & The Unopposed Alpha-Stimulation Phenomenon

Acute stimulant intoxication triggers a triad of cardiovascular pathophysiology:

Severe Coronary Vasospasm: Mediated by intense post-synaptic vascular alpha-1 adrenergic receptor stimulation in epicardial coronary arteries.

Myocardial Oxygen Supply-Demand Mismatch: Concurrently, marked beta-1 adrenergic stimulation drives profound sinus tachycardia, increased inotropic contractility, elevated systemic vascular resistance, and severe systolic hypertension, drastically elevating myocardial work and oxygen consumption.

Platelet Aggregation & In Situ Thrombosis: Cocaine directly enhances platelet alpha-granule release, increases thromboxane A 2 A_2 A 2 ​ production, elevates tissue factor and plasminogen activator inhibitor-1 (PAI-1), and damages vascular endothelium, promoting acute intracoronary thrombus formation even in angiographically normal vessels.

Caution

The Unopposed Alpha-Adrenergic Stimulation Phenomenon: Administering a pure non-selective or beta-1 selective beta-blocker (such as propranolol , metoprolol , or atenolol ) to a patient with acute stimulant toxicity is strictly contraindicated .

Pathophysiologic Mechanism: Beta-2 adrenergic receptors in peripheral arterial beds mediate vasodilation. When a beta-blocker selectively antagonizes beta-1 and beta-2 receptors in the presence of massive circulating catecholamines, the counter-regulatory vasodilatory mechanism is abolished. Unchecked catecholamines act exclusively on vascular alpha-1 adrenergic receptors , precipitating catastrophic unopposed alpha vasoconstriction .

Clinical Consequences: Paradoxical, malignant surges in systemic blood pressure, acute aortic dissection, severe coronary arterial spasm, acute left ventricular failure, and extensive transmural myocardial infarction.

Hemodynamic Crisis Protocol

First-Line Pharmacotherapy: Administer intravenous benzodiazepines (lorazepam 2 to 4 mg IV or diazepam 5 to 10 mg IV every 5 to 10 minutes). Benzodiazepines enhance central GABAergic tone, suppressing sympathetic outflow from the brainstem rostral ventrolateral medulla, reducing heart rate, blood pressure, psychomotor agitation, and myocardial oxygen demand.

Coronary Vasospasm & Severe Hypertension:

Sublingual or IV Nitroglycerin: Direct nitric oxide donor inducing rapid coronary and systemic venodilation/arteriodilation.

Intravenous Calcium Channel Blockers: Diltiazem (0.25 mg/kg IV bolus followed by infusion) or verapamil provides coronary vasodilation and controls supraventricular tachycardias.

Phentolamine: A competitive, non-selective alpha-1 and alpha-2 adrenergic antagonist (1 to 5 mg IV bolus every 5 to 10 minutes) is the definitive antidote for severe stimulant-induced hypertensive crisis and refractory coronary spasm.

Combined Alpha-Beta Blockade: If beta-blockade is deemed clinically necessary after adequate vasodilatory and benzodiazepine therapy, labetalol (a combined alpha-1 and non-selective beta blocker with a 1:7 alpha-to-beta antagonistic ratio parenterally) may be utilized with caution, although pure vasodilators remain preferred. STIMULANT-INDUCED HYPERTENSIVE CRISIS / CHEST PAIN ALGORITHM:

  • [Acute Cocaine / Methamphetamine Toxicity Presenting with Chest Pain / Malignant Hypertension]
  • │
  • ▼
  • [Administer High-Dose IV Benzodiazepines (Lorazepam 2-4 mg IV)]
  • (Attenuates Central Sympathetic Surge)
  • │
  • ┌────────────────────────┴────────────────────────┐
  • ▼ ▼
  • [Persistent Coronary Ischemia / Chest Pain] [Persistent Severe Hypertension (SBP > 180)]
  • │ │
  • ▼ ▼
  • [Sublingual/IV Nitroglycerin or Diltiazem] [IV Phentolamine (1-5 mg IV) or Nitroglycerin]
  • │ │
  • └────────────────────────┬────────────────────────┘
  • ▼
  • [STRICT CONTRAINDICATION: PURE BETA-BLOCKERS]
  • (Avoid Metoprolol, Propranolol, Atenolol)
  • Hyperthermia, Rhabdomyolysis & Acute Kidney Injury

Severe stimulant toxicity frequently manifests as malignant hyperthermia, where core body temperature exceeds 40.5 ∘ C 40.5^\circ\text{C} 40. 5 ∘ C ( 105 ∘ F 105^\circ\text{F} 10 5 ∘ F ) . This hyperpyrexic state results from the convergence of:

Uncontrolled, violent psychomotor agitation and muscle fasciculations producing massive metabolic heat.

Intense cutaneous vasoconstriction (alpha-1 mediated) preventing convective and evaporative heat loss.

Direct hypothalamic dopaminergic dysregulation disrupting central thermoregulatory set points.

Downstream Pathological Cascade:

Rhabdomyolysis: Hyperpyrexia and continuous muscle contraction trigger skeletal muscle cell membrane breakdown, releasing massive quantities of myoglobin, creatine kinase (CK > 10 , 000 – 100 , 000 U/L >10,000\text{–}100,000\text{ U/L} > 10 , 000 – 100 , 000 U/L ), potassium, and phosphate into the circulation.

Myoglobinuric Acute Kidney Injury (AKI): Filtered myoglobin precipitates in renal tubules under acidic conditions, causing direct tubular cytotoxicity, renal vasoconstriction, and cast nephropathy.

Disseminated Intravascular Coagulation (DIC): Extreme temperatures trigger widespread endothelial injury, activating systemic coagulation cascades, consuming platelets and clotting factors, and precipitating catastrophic microvascular thrombosis and hemorrhagic shock.

Excited Delirium & Agitation Management

Excited delirium is an extreme psychiatric and physiological emergency characterized by acute delirium, intense psychomotor agitation, paranoia, hallucinations, diaphoresis, hyperthermia, and superhuman physical exertion followed by sudden cardiopulmonary collapse.

Primary Treatment: Immediate parenteral sedation with intravenous or intramuscular benzodiazepines (midazolam 5 to 10 mg IM or lorazepam 2 to 4 mg IV/IM), repeated rapidly until the patient is calm. Immediate external active cooling (ice-water immersion, evaporative mist cooling, ice packs in axillary and inguinal creases) and aggressive intravenous crystalloid hydration ( 20 to 40 mL/kg/hr 20\text{ to }40\text{ mL/kg/hr} 20 to 40 mL/kg/hr of normal saline adjusted to maintain urine output ≥ 100 – 200 mL/hr \ge 100\text{–}200\text{ mL/hr} ≥ 100 – 200 mL/hr ).

The Antipsychotic Hazard: First-generation antipsychotics (e.g., haloperidol, fluphenazine) are contraindicated in acute stimulant hyperthermic toxicity. Haloperidol possesses potent anticholinergic and dopaminergic antagonist properties that impair sweating, block peripheral vasodilation, and severely cripple heat dissipation. Furthermore, haloperidol lowers the seizure threshold and significantly prolongs the QTc interval, exacerbating the risk of fatal ventricular dysrhythmias.

3. Pharmacotherapy Landscape & Landmark Clinical Trials

An essential concept for the CARN-AP examination is that there are NO FDA-approved medications for the treatment of Cocaine Use Disorder or Methamphetamine Use Disorder. All pharmacological interventions represent off-label applications supported by varying levels of clinical trial evidence.

The Landmark ADAPT-2 Trial (Trivedi et al., 2021)

The ADAPT-2 trial ( Accelerating the Development of Addictive Pharmacotherapy Treatments for Methamphetamine Use Disorder ), published in the New England Journal of Medicine , represents the most significant breakthrough in pharmacotherapy for methamphetamine use disorder to date:

Study Design: A multisite, double-blind, two-stage, placebo-controlled randomized trial evaluating 403 adult participants with moderate-to-severe methamphetamine use disorder.

Intervention Regimen:

Oral Extended-Release Bupropion: Initiated at 150 mg/day and titrated to 450 mg daily orally.

Injectable Extended-Release Naltrexone: Administered as 380 mg intramuscularly once every 3 weeks (rather than the standard 4-week interval used for alcohol and opioid dependence, to maintain higher steady-state therapeutic plasma concentrations).

Mechanistic Synergy: Bupropion is a dual norepinephrine and dopamine reuptake inhibitor (NDRI) and non-competitive nicotinic acetylcholine receptor antagonist; it blunts dysphoric stimulant withdrawal and craving by restoring basal monoaminergic tone. Naltrexone is a mu-opioid receptor antagonist that modulates endogenous endorphin and dynorphin reward circuits implicated in stimulant reinforcement.

Trial Findings: The weighted response rate (verified methamphetamine-negative urine drug screens) across stages was 13.6% in the active treatment group versus 2.5% in the placebo group ( P < 0.001 P < 0.001 P < 0.001 ). The calculated Number Needed to Treat (NNT) was 9 . Adverse events included gastrointestinal distress, nausea, headache, and insomnia, with no significant differences in serious adverse events.

Other Investigated Pharmacotherapies

Topiramate: A sulfamate-substituted monosaccharide that enhances GABA-A receptor facilitation, antagonizes AMPA and kainate excitatory glutamate receptors, and weakly inhibits carbonic anhydrase. Multiple clinical trials demonstrate that topiramate (titrated slowly to 200 to 300 mg/day in divided doses) significantly promotes continuous abstinence and reduces craving in both cocaine and methamphetamine use disorders. Primary adverse effects include paresthesias, psychomotor slowing, cognitive word-finding difficulty ("dopamax"), and weight loss.

Mirtazapine: A noradrenergic and specific serotonergic antidepressant ( N a S S A NaSSA N a SS A ) that acts as an antagonist at central presynaptic alpha-2 auto- and hetero-receptors, while blocking post-synaptic 5 -HT 2 5\text{-HT}_2 5 -HT 2 ​ and 5 -HT 3 5\text{-HT}_3 5 -HT 3 ​ receptors and histamine H 1 H_1 H 1 ​ receptors. Randomized trials (Colfax et al., Coffin et al.) demonstrated that mirtazapine ( 30 mg daily at bedtime ) significantly reduced methamphetamine use, depressive symptoms, and high-risk sexual behaviors among men who have sex with men (MSM) and transgender women.

Psychostimulant Agonist Replacement Therapy: Off-label evaluation of prescription stimulants (e.g., extended-release mixed amphetamine salts, methylphenidate, lisdexamfetamine) has shown modest benefit in severe treatment-refractory cases, functioning analogously to methadone for opioids. However, evidence remains mixed, and diversion risk requires strict clinical oversight.

Summary of Off-Label Pharmacotherapies

Medication Proposed Mechanism Dosing Protocol Target Population / Evidence Base

Bupropion XR + Naltrexone XR (ADAPT-2) NDRI + Mu-opioid receptor antagonism Bupropion 450 mg PO daily + Naltrexone 380 mg IM q3 weeks Moderate-to-severe Methamphetamine Use Disorder; highest randomized trial evidence (NNT = 9)

Topiramate GABA-A PAM; AMPA/kainate glutamate antagonist 50 mg daily titrated up to 100–150 mg PO BID Cocaine & Methamphetamine Use Disorders; reduces craving, blunts subjective euphoria

Mirtazapine Alpha-2 adrenergic antagonist; 5 -HT 2 / 3 5\text{-HT}_{2/3} 5 -HT 2/3 ​ and H 1 H_1 H 1 ​ blocker 30 mg PO at bedtime Methamphetamine use in MSM; improves sleep, appetite, depressive symptoms, reduces use

Modafinil Weak atypical DAT inhibitor; orexin/glutamate activator 200–400 mg PO daily Cocaine use disorder; modest efficacy primarily in patients without concurrent alcohol use

4. Psychosocial Interventions: The Cornerstone of Treatment

Because pharmacotherapies provide only adjunctive benefit, psychosocial and behavioral interventions constitute the primary standard of care for stimulant use disorders. PSYCHOSOCIAL HIERARCHY OF EVIDENCE IN STIMULANT USE DISORDER:

  • ┌────────────────────────────────────────────────────────┐
  • │ CONTINGENCY MANAGEMENT (CM) │ ── Highest Effect Size (d ≈ 0.60 - 0.80)
  • │ (Objective reinforcement, voucher / fishbowl system) │ Superior retention and verified abstinence
  • ├────────────────────────────────────────────────────────┤
  • │ COGNITIVE BEHAVIORAL THERAPY (CBT) │ ── Moderate Effect Size (d ≈ 0.35 - 0.45)
  • │ (Relapse prevention, trigger analysis, coping skills) │ Durable post-treatment relapse prevention
  • ├────────────────────────────────────────────────────────┤
  • │ THE MATRIX MODEL │ ── Comprehensive 16-Week IOP Platform
  • │ (Structured behavioral, psychoeducation, family, UDS) │ Optimized for ambulatory methamphetamine care
  • └────────────────────────────────────────────────────────┘
  • Contingency Management (CM)

Contingency Management is grounded in principles of operant conditioning, delivering immediate, tangible positive reinforcement (rewards) upon objective verification of the target behavior (e.g., stimulant-negative urine drug screens):

Empirical Stature: Over three decades of randomized controlled trials demonstrate that CM produces the largest effect size ( d ≈ 0.60 to 0.80 d \approx 0.60\text{ to }0.80 d ≈ 0.60 to 0.80 ) of any therapeutic intervention for stimulant use disorders, significantly outperforming standard counseling, 12-step programs, and pharmacotherapy in achieving continuous abstinence and treatment retention.

Implementation Models:

Voucher-Based Reinforcement (Higgins Model): Patients earn vouchers with monetary value redeemable for prosocial goods/services. The voucher value escalates with consecutive drug-negative urine tests (e.g., $2.50 for the first test, increasing by $1.25 for each successive negative test). A positive or missed test resets the voucher value back to baseline, introducing an immediate behavioral consequence.

Fishbowl Prize Method (Petry Model): Patients submitting negative urine screens earn draws from a prize bowl containing slips: 50% verbal affirmation ("Good job!"), 42% small prizes ($1 to $5), 7% medium prizes ($20), and 1% jumbo prizes ($100). The variable-ratio reinforcement schedule enhances engagement while significantly reducing programmatic costs.

Cognitive Behavioral Therapy (CBT)

CBT operates on the premise that substance-seeking behaviors are learned through classical conditioning, instrumental learning, and maladaptive cognitive schemas:

Functional Analysis: Clinicians guide patients to analyze the "5 Ws" of stimulant use: Who they use with, What triggers use, Where they obtain/use, When urges peak, and Why they use (internal emotional states).

Skill Acquisition: Focuses on craving management, developing refusal assertiveness, avoiding "people, places, and things," restructuring automatic euphoric recall, and managing the "Abstinence Violation Effect" (preventing a minor slip from escalating into a catastrophic relapse).

The Matrix Model

The Matrix Model is an intensive outpatient, 16-week programmatic platform developed specifically for stimulant (cocaine and methamphetamine) dependence:

Multimodal Integration: Combines weekly individual counseling, early recovery skills groups, 12-step facilitation, relapse prevention groups, family education workshops, and mandatory, twice-weekly randomized urine toxicology monitoring.

Therapeutic Stance: The clinician serves as an active, authentic, non-confrontational "coach," fostering self-efficacy and establishing predictable structure during the vulnerable early withdrawal period.